PURPOSE: Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication. PATIENTS AND METHODS: Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models. RESULTS: Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas. CONCLUSION: Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials.

Cytogenetic Prognostication Within Medulloblastoma Subgroups / Shih, Dj; Northcott, Pa; Remke, M; Korshunov, A; Ramaswamy, V; Kool, M; Luu, B; Yao, Y; Wang, X; Dubuc, Am; Garzia, L; Peacock, J; Mack, Sc; Wu, X; Rolider, A; Morrissy, As; Cavalli, Fm; Jones, Dt; Zitterbart, K; Faria, Cc; Schüller, U; Kren, L; Kumabe, T; Tominaga, T; Shin Ra, Y; Garami, M; Hauser, P; Chan, Ja; Robinson, S; Bognár, L; Klekner, A; Saad, Ag; Liau, Lm; Albrecht, S; Fontebasso, A; Cinalli, G; DE ANTONELLIS, Pasqualino; Zollo, Massimo; Cooper, Mk; Thompson, Rc; Bailey, S; Lindsey, Jc; Di Rocco, C; Massimi, L; Michiels, Em; Scherer, Sw; Phillips, Jj; Gupta, N; Fan, X; Muraszko, Km; Vibhakar, R; Eberhart, Cg; Fouladi, M; Lach, B; Jung, S; Wechsler Reya, Rj; Fèvre Montange, M; Jouvet, A; Jabado, N; Pollack, If; Weiss, Wa; Lee, Jy; Cho, Bk; Kim, Sk; Wang, Kc; Leonard, Jr; Rubin, Jb; de Torres, C; Lavarino, C; Mora, J; Cho, Yj; Tabori, U; Olson, Jm; Gajjar, A; Packer, Rj; Rutkowski, S; Pomeroy, Sl; French, Pj; Kloosterhof, Nk; Kros, Jm; Van Meir, Eg; Clifford, Sc; Bourdeaut, F; Delattre, O; Doz, Ff; Hawkins, Ce; Malkin, D; Grajkowska, Wa; Perek Polnik, M; Bouffet, E; Rutka, Jt; Pfister, Sm; Taylor, M. d.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 32:9(2014), pp. 886-896. [10.1200/JCO.2013.50.9539]

Cytogenetic Prognostication Within Medulloblastoma Subgroups

DE ANTONELLIS, PASQUALINO;ZOLLO, MASSIMO;
2014

Abstract

PURPOSE: Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication. PATIENTS AND METHODS: Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models. RESULTS: Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas. CONCLUSION: Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials.
2014
Cytogenetic Prognostication Within Medulloblastoma Subgroups / Shih, Dj; Northcott, Pa; Remke, M; Korshunov, A; Ramaswamy, V; Kool, M; Luu, B; Yao, Y; Wang, X; Dubuc, Am; Garzia, L; Peacock, J; Mack, Sc; Wu, X; Rolider, A; Morrissy, As; Cavalli, Fm; Jones, Dt; Zitterbart, K; Faria, Cc; Schüller, U; Kren, L; Kumabe, T; Tominaga, T; Shin Ra, Y; Garami, M; Hauser, P; Chan, Ja; Robinson, S; Bognár, L; Klekner, A; Saad, Ag; Liau, Lm; Albrecht, S; Fontebasso, A; Cinalli, G; DE ANTONELLIS, Pasqualino; Zollo, Massimo; Cooper, Mk; Thompson, Rc; Bailey, S; Lindsey, Jc; Di Rocco, C; Massimi, L; Michiels, Em; Scherer, Sw; Phillips, Jj; Gupta, N; Fan, X; Muraszko, Km; Vibhakar, R; Eberhart, Cg; Fouladi, M; Lach, B; Jung, S; Wechsler Reya, Rj; Fèvre Montange, M; Jouvet, A; Jabado, N; Pollack, If; Weiss, Wa; Lee, Jy; Cho, Bk; Kim, Sk; Wang, Kc; Leonard, Jr; Rubin, Jb; de Torres, C; Lavarino, C; Mora, J; Cho, Yj; Tabori, U; Olson, Jm; Gajjar, A; Packer, Rj; Rutkowski, S; Pomeroy, Sl; French, Pj; Kloosterhof, Nk; Kros, Jm; Van Meir, Eg; Clifford, Sc; Bourdeaut, F; Delattre, O; Doz, Ff; Hawkins, Ce; Malkin, D; Grajkowska, Wa; Perek Polnik, M; Bouffet, E; Rutka, Jt; Pfister, Sm; Taylor, M. d.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 32:9(2014), pp. 886-896. [10.1200/JCO.2013.50.9539]
File in questo prodotto:
File Dimensione Formato  
Shih_Journal-of-Clinical-Oncology_2014.pdf

non disponibili

Descrizione: pdf articolo
Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 400.77 kB
Formato Adobe PDF
400.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/577671
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 236
  • ???jsp.display-item.citation.isi??? 201
social impact